Penumbra (NYSE:PEN) Stock Rating Lowered by Needham & Company LLC

Penumbra (NYSE:PEN) was downgraded by stock analysts at Needham & Company LLC from a “buy” rating to a “hold” rating in a note issued to investors on Friday, Marketbeat reports.

Several other analysts have also issued reports on PEN. Evercore ISI restated an “outperform” rating and issued a $340.00 price objective on shares of Penumbra in a research note on Monday, January 5th. Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a research note on Monday, December 29th. William Blair cut shares of Penumbra from an “outperform” rating to a “market perform” rating in a research report on Thursday. Wall Street Zen upgraded shares of Penumbra from a “hold” rating to a “buy” rating in a report on Saturday, December 20th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $355.00 price objective on shares of Penumbra in a research report on Wednesday, December 17th. Seven analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, Penumbra currently has a consensus rating of “Hold” and an average target price of $355.88.

Penumbra Stock Performance

Shares of PEN stock opened at $350.93 on Friday. The company has a fifty day moving average price of $303.54 and a two-hundred day moving average price of $269.65. Penumbra has a one year low of $221.26 and a one year high of $352.15. The stock has a market cap of $13.74 billion, a P/E ratio of 83.95, a P/E/G ratio of 2.14 and a beta of 0.71. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.07. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The company had revenue of $354.69 million for the quarter, compared to analyst estimates of $340.77 million. During the same period in the previous year, the business earned $0.85 EPS. Penumbra’s revenue for the quarter was up 17.8% compared to the same quarter last year. As a group, equities analysts predict that Penumbra will post 3.67 EPS for the current year.

Insider Transactions at Penumbra

In related news, EVP Johanna Roberts sold 300 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $300.13, for a total transaction of $90,039.00. Following the transaction, the executive vice president directly owned 63,836 shares of the company’s stock, valued at approximately $19,159,098.68. This trade represents a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Harpreet Grewal sold 186 shares of Penumbra stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $312.64, for a total transaction of $58,151.04. Following the completion of the sale, the director owned 8,230 shares of the company’s stock, valued at $2,573,027.20. This trade represents a 2.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 34,144 shares of company stock worth $10,260,127 over the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Abbot Financial Management Inc. raised its position in shares of Penumbra by 1.3% in the third quarter. Abbot Financial Management Inc. now owns 3,254 shares of the company’s stock valued at $824,000 after buying an additional 42 shares in the last quarter. Glenview Trust Co grew its position in Penumbra by 5.0% during the third quarter. Glenview Trust Co now owns 904 shares of the company’s stock worth $229,000 after buying an additional 43 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its stake in Penumbra by 0.5% during the 3rd quarter. Northwestern Mutual Investment Management Company LLC now owns 8,693 shares of the company’s stock worth $2,202,000 after acquiring an additional 47 shares during the period. GAMMA Investing LLC raised its holdings in Penumbra by 7.3% in the 2nd quarter. GAMMA Investing LLC now owns 761 shares of the company’s stock valued at $195,000 after acquiring an additional 52 shares in the last quarter. Finally, Covestor Ltd raised its holdings in Penumbra by 53.0% in the 3rd quarter. Covestor Ltd now owns 179 shares of the company’s stock valued at $46,000 after acquiring an additional 62 shares in the last quarter. 88.88% of the stock is owned by institutional investors.

Penumbra News Summary

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.